Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology
Commercializing Core Cell-free DNA Technology Beyond Reproductive Health
PR Newswire
SAN CARLOS, Calif., June 21, 2018
SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ -- Natera, Inc. NTRA, a leader in genetic testing and cell-free DNA analysis, will share data and roadmap for its emerging businesses in renal transplantation and oncology, during an investor call on June 27, 2018.
Date: |
June 27, 2018 |
Time: |
1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In US/Canada: |
(877) 823-0171 |
Live Dial-In US/ Canada/ |
|
International: |
(617) 500-6932 |
Conference ID: |
9888083 |
Webcast Link: |
A webcast replay will be available at investor.natera.com.
About Natera
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer and organ transplantation including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter.
Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Barbara Sullivan, Sullivan & Associates, 714-374-6174, bsullivan@sullivanpr.com
View original content with multimedia:http://www.prnewswire.com/news-releases/natera-to-host-investor-conference-call-to-discuss-strategic-roadmap-in-organ-transplantation-and-oncology-300670435.html
SOURCE Natera, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.